Hill J S, Yang D, Nikazy J, Curtiss L K, Sparrow J T, Wong H
Lipid Research Laboratory, West Los Angeles Veterans Affairs Medical Center, Los Angeles, California 90073, USA.
J Biol Chem. 1998 Nov 20;273(47):30979-84. doi: 10.1074/jbc.273.47.30979.
To specify and localize carboxyl-terminal domain functions of human hepatic lipase (HL) and human lipoprotein lipase (LPL), two subdomain chimeras were created in which portions of the carboxyl-terminal domain were exchanged between the two lipases. The first chimera (HL-LPLC1) was composed of residues 1-344 of human HL, residues 331-388 of human LPL, and residues 415-476 of human HL. The second chimera (HL-LPLC2) consisted of just two segments, residues 1-414 of human HL and residues 389-448 of human LPL. These chimeric constructs effectively divided the HL C-terminal domain into halves, with corresponding LPL sequences either in the first or second portion of that domain. Both chimeras were lipolytically active and hydrolyzed triolein emulsions to a similar extent compared with native HL and LPL. Heparin-Sepharose chromatography demonstrated that HL-LPLC1 and HL-LPLC2 eluted at 0.80 and 1.3 M NaCl, respectively, elution positions that corresponded to native HL and LPL. Hence, substitution of LPL sequences into the HL carboxyl-terminal domain resulted in the production of functional lipases, but with distinct heparin binding properties. In addition, HL-LPLC2 trioleinase activity was responsive to apoC-II activation, although the -fold stimulation was less than that observed with native LPL. Moreover, an apoC-II fragment (residues 44-79) was specifically cross-linked to LPL and HL-LPLC2, but not to HL or HL-LPLC1. Finally, both chimeras hydrolyzed phospholipid with a specific activity similar to that of HL, which was unaffected by the presence of apoC-II. These findings indicated that in addition to a region found within the amino-terminal domain of LPL, apoC-II also interacted with the last half of the carboxyl-terminal domain (residues 389-448) to achieve maximal lipolytic activation. In addition, the relative heparin affinity of HL and LPL was determined by the final 60 carboxyl-terminal residues of each enzyme.
为了明确和定位人肝脂酶(HL)和人脂蛋白脂酶(LPL)的羧基末端结构域功能,构建了两个亚结构域嵌合体,其中两个脂酶的羧基末端结构域部分进行了交换。第一个嵌合体(HL-LPLC1)由人HL的1-344位残基、人LPL的331-388位残基和人HL的415-476位残基组成。第二个嵌合体(HL-LPLC2)仅由两段组成,即人HL的1-414位残基和人LPL的389-448位残基。这些嵌合构建体有效地将HL的C末端结构域分成两半,相应的LPL序列位于该结构域的第一部分或第二部分。与天然HL和LPL相比,两个嵌合体均具有脂解活性,且对三油精乳液的水解程度相似。肝素-琼脂糖凝胶色谱显示,HL-LPLC1和HL-LPLC2分别在0.80和1.3 M NaCl处洗脱,洗脱位置与天然HL和LPL相对应。因此,将LPL序列替换到HL羧基末端结构域中产生了具有功能的脂酶,但具有不同的肝素结合特性。此外,HL-LPLC2的三油精酶活性对载脂蛋白C-II(apoC-II)激活有反应,尽管刺激倍数低于天然LPL。此外,一个apoC-II片段(44-79位残基)特异性地与LPL和HL-LPLC2交联,但不与HL或HL-LPLC1交联。最后,两个嵌合体水解磷脂的比活性与HL相似,且不受apoC-II存在的影响。这些发现表明,除了在LPL氨基末端结构域内发现的一个区域外,apoC-II还与羧基末端结构域的后半部分(389-448位残基)相互作用,以实现最大程度的脂解激活。此外,HL和LPL的相对肝素亲和力由每种酶的最后60个羧基末端残基决定。